GlaxoSmithKline and Vir Biotechnology have taken a big step toward authorization of an intramuscular formulation of their anti-SARS-CoV-2 antibody sotrovimab. The partners have filed for FDA emergency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback